KHKentaro Hata

Kentaro Hata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kentaro Hata has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunophenotyping of T Cells in Lung Malignancies and Cryptogenic Organizing Pneumonia

    by Toyoshi Yanagihara, Kentaro Hata, Keisuke Matsubara, Kazufumi Kunimura, Kunihiro Suzuki, Kazuya Tsubouchi, Satoshi Ikegame, Yoshinori Fukui, Isamu Okamoto

    Background: Lung malignancies, including cancerous lymphangitis and lymphomas, can mimic interstitial lung diseases like cryptogenic organizing pneumonia (COP) on imaging, leading to diagnostic delays. We aimed to identify potential biomarkers to distinguish between these conditions. Methods: We analyzed bronchoalveolar lavage fluid from 8 patients (4 COP, mean age 59.8 ± 13.5 years; 4 lung malignancies including 2 cancerous lymphangitis, 1 MALT lymphoma, and 1 diffuse large B cell lymphoma, mean age 67.8 ± 4.5 years) using mass cytometry with 35 T cell markers. Data were analyzed using principal component analysis (PCA) and unsupervised Citrus clustering. Results: PCA of T cell marker intensities effectively separated the two groups, with IL-2Rα, PD-L2, CD45RA, CD44, and OX40 being the top discriminating markers. Citrus analysis showed a significant increase in the CD16+ CD4+ and CD16+ CD8+ T cell populations in the COP group compared to lung malignancies. Conclusions: Our findings reveal distinct T cell immunophenotypes in COP versus lung malignancies, particularly increased CD16+ T cells in COP, which could serve as potential diagnostic biomarkers.

  • Open Access

    Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis

    by Toyoshi Yanagihara, Kentaro Hata, Keisuke Matsubara, Kazufumi Kunimura, Kunihiro Suzuki, Kazuya Tsubouchi, Satoshi Ikegame, Yoshihiro Baba, Yoshinori Fukui, Isamu Okamoto

    Anticancer treatments can result in various adverse effects, including infections due to immune suppression/dysregulation and drug-induced toxicity in the lung. One of the major opportunistic infections is Pneumocystis jirovecii pneumonia (PCP), which can cause severe respiratory complications and high mortality rates. Cytotoxic drugs and immune-checkpoint inhibitors (ICIs) can induce interstitial lung diseases (ILDs). Nonetheless, the differentiation of these diseases can be difficult, and the pathogenic mechanisms of such diseases are not yet fully understood. To better comprehend the immunophenotypes, we conducted an exploratory mass cytometry analysis of immune cell subsets in bronchoalveolar lavage fluid from patients with PCP, cytotoxic drug-induced ILD (DI-ILD), and ICI-associated ILD (ICI-ILD) using two panels containing 64 markers. In PCP, we observed an expansion of the CD16+ T cell population, with the highest CD16+ T proportion in a fatal case. In ICI-ILD, we found an increase in CD57+ CD8+ T cells expressing immune checkpoints (TIGIT+ LAG3+ TIM-3+ PD-1+), FCRL5+ B cells, and CCR2+ CCR5+ CD14+ monocytes. These findings uncover the diverse immunophenotypes and possible pathomechanisms of cancer treatment-related pneumonitis.


  • Open Access

    Altered macrophage phenotypes in a case of autoimmune pulmonary alveolar proteinosis

    by Kentaro Hata, Toyoshi Yanagihara, Keisuke Matsubara, Kazufumi Kunimura, Daisuke Eto, Kunihiro Suzuki, Kazuya Tsubouchi, Satoshi Ikegame, Yoshinori Fukui, Isamu Okamoto

    Pulmonary alveolar proteinosis (PAP) is an ultra-rare disease characterised by abnormal accumulation of surfactant components in the alveoli [1]. The majority of cases are of an autoimmune nature (previously named primary or idiopathic) and are linked to the presence of an autoantibody targeting granulocyte–macrophage colony-stimulating factor (GM-CSF) [1]. This anti-GM-CSF antibody impedes the ability of alveolar macrophages to remove pulmonary surfactant. As a consequence, a significant proportion of patients experience progressive respiratory failure and immune deficiency [1]. While considerable progress has been made in understanding the pathophysiology of PAP over the past two decades, there has yet to be an in-depth analysis of macrophage phenotypes in human lungs with PAP. Our study reports on a case of PAP and presents a novel approach to analysing macrophage phenotypes in this condition using mass cytometry.


  • Mass cytometry analysis of B-cell populations in extranodal marginal-zone lymphoma of mucosa-associated lymphoid tissue of the lung

    by Toyoshi Yanagihara, Kentaro Hata, Keisuke Matsubara, Kazufumi Kunimura, Kunihiro Suzuki, Kazuya Tsubouchi, Satoshi Ikegame, Yoshihiro Baba, Yoshinori Fukui, Isamu Okamoto

  • Open Access

    Immune-checkpoint kinetics for T cells in anti-MDA5 positive interstitial lung disease

    by Kunihiro Suzuki, Toyoshi Yanagihara, Koichiro Matsumoto, Sy Giin Chong, Hiroyuki Ando, Maako Ide, Masako Arimura-Omori, Kentaro Hata, Naoki Hamada